Table 1.

Sustained Virologic Response Rates According to Patient and Disease Characteristics in Treatment-Naive Patients Receiving Telaprevir or Boceprevir plus Peginterferon Alfa/Ribavirin Compared with Peginterferon Alfa/Ribavirin Alone

	Sustained Virologic Response Rate (%)
	TPV 12 and Peg/RBV 24-48	Peg/RBV 48	BOC 44 and Peg/RBV 24-48	Peg/RBV 48
Viral load (IU/mL)
< 800,000	78	70	85	64
≥ 800,000	74	36	63	33
Race
White	75	46	68	40
Black	62	25	53	23
Fibrosis stage
0-2	77	47	67	38
3-4	62	33	52	38
Body mass index (kg/m2)
< 25	83	44	67	47
25-30	67	45	65	33
> 30	71	41	66	33

TPV 12 indicates patients receiving telaprevir for 12 weeks; Peg/RBV 24-48, peginterferon alfa and ribavirin for 24 to 48 weeks; Peg/RBV 48, peginterferon alfa and ribavirin for 48 weeks; BOC 44, boceprevir for 44 weeks. Adapted from Jacobson et al2 and Poordad et al.4